Unity Biotechnology, Inc.: common shares outstanding

What this measure means

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Exact concept: us-gaap:CommonStockSharesOutstanding. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2017-12-31 to 2024-12-31. The SEC response was captured on 2026-09-21.

Selected filing history

Related financial histories

• Unity Biotechnology, Inc.: total assets
• Unity Biotechnology, Inc.: total liabilities
• Unity Biotechnology, Inc.: stockholders equity
• Unity Biotechnology, Inc.: cash and cash equivalents
• Unity Biotechnology, Inc.: net income or loss
• Unity Biotechnology, Inc.: operating cash flow
• Unity Biotechnology, Inc.: capital expenditure payments
• Unity Biotechnology, Inc.: contract revenue excluding tax
• Unity Biotechnology, Inc.: financing cash flow
• Unity Biotechnology, Inc.: investing cash flow
• Unity Biotechnology, Inc.: retained earnings or deficit
• Unity Biotechnology, Inc.: basic weighted-average shares
• Unity Biotechnology, Inc.: diluted weighted-average shares
• Unity Biotechnology, Inc.: basic earnings per share
• Unity Biotechnology, Inc.: diluted earnings per share
• Unity Biotechnology, Inc.: net property, plant and equipment
• Unity Biotechnology, Inc.: share-based compensation expense
• Unity Biotechnology, Inc.: operating income or loss
• Unity Biotechnology, Inc.: current assets
• Unity Biotechnology, Inc.: interest expense
• Unity Biotechnology, Inc.: current liabilities
• Unity Biotechnology, Inc.: current accounts payable
• Unity Biotechnology, Inc.: operating expenses
• Unity Biotechnology, Inc.: research and development expense
• Unity Biotechnology, Inc.: cash including restricted cash
• Unity Biotechnology, Inc.: accumulated other comprehensive income or loss
• Unity Biotechnology, Inc.: operating lease right-of-use asset
• Unity Biotechnology, Inc.: operating lease liability
• Unity Biotechnology, Inc.: long-term debt
• Unity Biotechnology, Inc.: gross property, plant and equipment
• Unity Biotechnology, Inc.: accumulated depreciation on property, plant and equipment
• Unity Biotechnology, Inc.: other noncurrent assets
• Unity Biotechnology, Inc.: other noncurrent liabilities
• Unity Biotechnology, Inc.: accrued current liabilities
• Unity Biotechnology, Inc.: prepaid expenses and other current assets
• Unity Biotechnology, Inc.: net deferred tax assets
• Unity Biotechnology, Inc.: comprehensive income or loss
• Unity Biotechnology, Inc.: general and administrative expense
• Unity Biotechnology, Inc.: depreciation expense
• Unity Biotechnology, Inc.: depreciation, depletion and amortization
• Unity Biotechnology, Inc.: other nonoperating income or expense
• Unity Biotechnology, Inc.: interest paid, net
• Unity Biotechnology, Inc.: proceeds from issuing common stock
• Unity Biotechnology, Inc.: operating lease payments
• Unity Biotechnology, Inc.: change in accounts payable

Inspect the source

Entity

Unity Biotechnology, Inc. / CIK 0001463361

Captured

2026-09-21T17:20:02.172Z

SEC response SHA-256

3a053da6593283127d75e18d8a30610d9d1d21e4b27888a8392c3866b9044953

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001463361.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))